The ICESTP Safety Panels™ 44 and 77 are fully functional secondary pharmacology panels designed to deliver quantitative, mechanism-rele-vant insights. ICESTP 77, in particular, is the first functional Safety 77 panel available in the market. These panels are built on the latest scientific consensus surrounding secondary pharmacology, as outlined in recent publications such as Nature Reviews Drug Discovery (2024).
ICE Bioscience Inc., established in 2010 in Beijing, focuses on an integrated biological services platform for innovative drug discovery, encompassing target identification and validation, lead compound screening, optimization, and pre-clinical candidate stages. It pioneers an innovative CRO+ model in biological and pharmacological research technologies across oncology, immunology, cardiovascular, central nervous system, and metabolism diseases.
ICE Bioscience expert electrophysiology team has led the way in early drug discovery since 2010, specializing in ion channel screening and cardiac safety assessment. Our reputation is built on comprehensive services from target validation to preclinical candidate identification.
Two prominent modalities within targeted protein degradation are PROTACs (Proteolysis Targeting Chimeras) and molecular glues. PROTACs function by recruiting an E3 ubiquitin ligase to a target protein, leading to its ubiquitination and subsequent degradation by the proteasome. This strategy enables the degradation of proteins considered "undruggable" by traditional small molecule inhibitors. On the other hand, molecular glues induce protein-protein interactions that result in the degradation of specific targets, providing an alternative approach to PROTACs.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
